EYE Share Price Performance
AU$0.14
-0.03 (-18.18%)
55.0% undervalued intrinsic discount
AU$0.30
Fair Value
Price AU$0.14
AnalystLowTarget AU$0.30
AnalystConsensusTarget AU$0.37
AnalystHighTarget AU$0.50
Fair ValueAU$0.30
Share Pricen/a
Nova Eye Medical Limited Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 18 Fair Values set on narratives written by author
EYE Community Narratives
AN
Fair Value
·Fair Value AU$0.3 55.0% undervalued intrinsic discount
US Market Dependence Will Constrain Earnings But Enable Novel Approaches
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value AU$0.37 63.8% undervalued intrinsic discount
US Demand And China Approval Will Boost Vision Care Access
0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
AN
Fair Value
·Fair Value AU$0.5 73.0% undervalued intrinsic discount
Aging Populations And MIGS Advances Will Expand Ophthalmic Markets
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Nova Eye Medical
55.0% undervalued intrinsic discount
US Market Dependence Will Constrain Earnings But Enable Novel Approaches
View narrativeAN
Updated 27 Apr
Nova Eye Medical
73.0% undervalued intrinsic discount
Aging Populations And MIGS Advances Will Expand Ophthalmic Markets
View narrativeAN
Published 1 Sep 2025
Nova Eye Medical
63.8% undervalued intrinsic discount
US Demand And China Approval Will Boost Vision Care Access
View narrativeAN
Published 16 May 2025
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
EYE: Reaffirmed 2026 Guidance Will Support Confidence In Undervalued Upside Potential
Fair Value: AU$0.3 55.0% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Aging Populations And MIGS Advances Will Expand Ophthalmic Markets
Fair Value: AU$0.5 73.0% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
US Demand And China Approval Will Boost Vision Care Access
Fair Value: AU$0.37 63.8% undervalued intrinsic discount
12 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Nova Eye Medical Limited Key Details
About EYE
- Founded
- 1970
- Employees
- n/a
- CEO
- WebsiteView website
Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. The company operates through Glaucoma Surgical Devices and AlphaRET segments. It offers 2RT, a proprietary laser technology to treat patients in early and intermediate age-related macular degeneration for the treatment of retinal disease. The company offers iTrack, a glaucoma surgical device to reduce intraocular pressure in patients glaucoma; iTrack Advance; and Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma. The company was formerly known as Ellex Medical Lasers Limited and changed its name to Nova Eye Medical Limited in July 2020. Nova Eye Medical Limited was incorporated in 1970 and is headquartered in Kent Town, Australia.
